Monitor future earnings reports for commentary on cash usage from the sale and changes in revenue trends due to the divestiture. The strategic pivot to NAD+ science may attract biotech-focused investors, but lack of financial disclosure limits immediate valuation impact.
Price Chart
Executive Summary
Niagen Bioscience, Inc. (NAGE) completed the all-cash sale of its ChromaDex analytical reference standards and services business to LGC Group's VHG Labs. The divestiture supports the company's strategic shift to focus exclusively on its NAD+ science platform, intellectual property, and commercial growth in the longevity sector. The transaction closed on February 24, 2026, with no financial terms disclosed.
Key Facts
- Niagen Bioscience sold its ChromaDex reference standards and services business to VHG Labs, part of LGC Group, in an all-cash transaction.
- The sale closed on February 24, 2026, the same day the Asset Purchase Agreement was signed.
- The divestiture is part of Niagen's strategy to exit non-core activities and focus on its NAD+ science platform and commercial growth.
- A transition services agreement was established, under which Niagen will provide operational and administrative services to LGC for up to six months post-closing.
- No financial terms of the transaction (e.g., sale price, revenue impact) were disclosed in the filing or press release.
Financial Impact
Unknown — transaction value not disclosed. Short-term cash inflow expected, but long-term revenue loss from divested business is unquantified.
Risk Factors
- Loss of recurring revenue from the divested reference standards business could pressure overall financial performance.
- Execution risk in focusing on the NAD+ platform without proven commercial scalability beyond current products.
- Market may view the lack of disclosed sale price as opacity, potentially affecting investor confidence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001386570-26-000003 |
| Exhibit: ex991-nagepressreleasexref.htm | 0001386570-26-000003 |
| Document: 0001386570-26-000003-index-headers.html | 0001386570-26-000003 |
| Document: 0001386570-26-000003-index.html | 0001386570-26-000003 |
| Document: 0001386570-26-000003.txt | 0001386570-26-000003 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 10, 2026 15w ago | 424B5 | $3.47 $2.69 | ▲ +22.48% | ▲ +26.47% | $2.49 (+28.10%) |
Jul 10, 2026 15w ago | EFFECT | $3.39 $2.68 | ▲ +20.94% | ▲ +23.58% | $2.49 (+26.40%) |
Jun 26, 2026 17w ago | S-3 | $3.30 $3.09 | ▲ +6.36% | ▲ +10.75% | $2.49 (+24.39%) |
May 6, 2026 24w ago | 8-K | $4.19 $3.53 | ▼ −15.75% | ▼ −19.58% | $2.49 (−40.45%) |
Mar 4, 2026 33w ago | 8-K | $5.10 $3.61 | ▼ −29.22% | ▼ −40.52% | $2.49 (−51.08%) |
Feb 26, 2026 34w ago | 8-K | $5.18 $3.79 | ▼ −26.83% | ▼ −34.58% | $2.49 (−51.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers